{"schema_version":"secwatch.filing_event.v1","accession":"0001831283-23-000034","form_type":"8-K","ticker":"LIANY","cik":"0001831283","company_name":"LianBio","filed_at":"2023-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.907145+00:00","generated_at":"2026-06-17T15:28:54.238013+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"LianBio reports FY2022 net loss of $110.3M; cash $302.4M with runway through end of 2024","bullets":["Net loss $18.3M in Q4 2022 ($21.2M in Q4 2021); FY2022 loss $110.3M vs $196.3M in 2021.","Cash, cash equivalents and marketable securities $302.4M at Dec 31, 2022, down $100.8M from 2021.","Phase 3 EXPLORER-CN trial of mavacamten completed patient visits; topline data expected mid-2023.","Entered commercial agreement with Pfizer for sisunatovir; received $20M upfront, eligible for up to $135M milestones.","Phase 3 LIBRA trial of TP-03 for Demodex blepharitis ongoing; data expected Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001831283-23-000034","json":"https://secwatch.observer/filing/0001831283-23-000034.json","markdown":"https://secwatch.observer/filing/0001831283-23-000034.md","text":"https://secwatch.observer/filing/0001831283-23-000034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831283/000183128323000034/0001831283-23-000034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831283/000183128323000034/lian-20230327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T15:28:54.238013+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0b3f1fa19a7aac0a37acd28fe8ba5b49534a3b76","claim":"LianBio reported financial results for the year ended December 31, 2022.","evidence_excerpt":"On March 27, 2023, LianBio issued a press release announcing its financial results for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831283/000183128323000034/0001831283-23-000034-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}